Trecondi Den europeiske union - norsk - EMA (European Medicines Agency)

trecondi

medac gesellschaft für klinische spezialpräparate mbh - treosulfan - hematopoietisk stamcelletransplantasjon - antineoplastiske midler - treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (allohsct) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.

Clarithromycin Accord 500 mg Norge - norsk - Statens legemiddelverk

clarithromycin accord 500 mg

accord healthcare b.v. - klaritromycin - tablett, filmdrasjert - 500 mg

Clarithromycin Accord 250 mg Norge - norsk - Statens legemiddelverk

clarithromycin accord 250 mg

accord healthcare b.v. - klaritromycin - tablett, filmdrasjert - 250 mg

Klacid OD 500 mg Norge - norsk - Statens legemiddelverk

klacid od 500 mg

orifarm as - klaritromycin - depottablett - 500 mg

Tobrasone 3 mg/ ml / 1 mg/ ml Norge - norsk - Statens legemiddelverk

tobrasone 3 mg/ ml / 1 mg/ ml

2care4 aps - tobramycin / deksametason - Øyedråper, suspensjon - 3 mg/ ml / 1 mg/ ml

Zitromax 500 mg Norge - norsk - Statens legemiddelverk

zitromax 500 mg

orifarm as - azitromycindihydrat - tablett, filmdrasjert - 500 mg

Clindamycin Navamedic 300 mg Norge - norsk - Statens legemiddelverk

clindamycin navamedic 300 mg

navamedic asa - klindamycinfosfat - infusjonsvæske, oppløsning - 300 mg

Clindamycin Navamedic 600 mg Norge - norsk - Statens legemiddelverk

clindamycin navamedic 600 mg

navamedic asa - klindamycinfosfat - infusjonsvæske, oppløsning - 600 mg

Abboticin 250 mg Norge - norsk - Statens legemiddelverk

abboticin 250 mg

amdipharm limited (1) - erytromycinstearat - tablett, drasjert - 250 mg

Vaxneuvance Den europeiske union - norsk - EMA (European Medicines Agency)

vaxneuvance

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumokokkerinfeksjoner - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. se avsnitt 4. 4 og 5. 1 for informasjon om beskyttelse mot spesifikke pneumokokserotyper. the use of vaxneuvance should be in accordance with official recommendations.